Simona Frezzini

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Sandro Pignata, Domenica Lorusso, Florence Joly et al. · The Lancet Oncology · 2021 · 149 citations

Medicine, Gynecology, Oncology +15

Autophagy inhibition reduces chemoresistance and tumorigenic potential of human ovarian cancer stem cells

Anna Pagotto, Giorgia Pilotto, Elena Laura Mazzoldi et al. · Cell Death and Disease · 2017 · 145 citations · Full text

Medicine, Cell Biology, Oncology +17

Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease

Maria Vittoria Dieci, Vassilena Tsvetkova, Gaia Griguolo et al. · Frontiers in Oncology · 2019 · 71 citations · Full text

Medicine, Cancer Biology, Oncology +16

A juxtacrine/paracrine loop between C-Kit and stem cell factor promotes cancer stem cell survival in epithelial ovarian cancer

Elena Laura Mazzoldi, Simona Pavan, Giorgia Pilotto et al. · Cell Death and Disease · 2019 · 52 citations · Full text

Medicine, Cell Biology, Oncology +17

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study

Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia et al. · International Journal of Gynecological Cancer · 2021 · 36 citations

Medicine, Gynecology, Oncology +17